Morgan Stanley has adjusted its price target for Align Technology (ALGN, Financial), reducing it from $272 to $249. Despite the reduction, the firm maintains an Overweight rating on the stock, indicating continued confidence in its potential.
The decision comes amid broader discussions in the Healthcare Services and Technology sectors, where policy considerations are expected to play a significant role. Investors are being urged to pay attention to underlying utilization trends across various segments, including managed care organizations (MCOs), distributors, providers, laboratories, and both dental and animal care sectors as the industry moves into the first quarter.
